HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3032-3038

  Perez, Edith A ^a   Suman, Vera J ^b   Davidson, Nancy E ^b   Martino, Silvana ^b   Kaufman, Peter A ^b   Lingle, Wilma L ^b   Flynn, Patrick J ^b   Ingle, James N ^b   Visscher, Daniel ^b   Jenkins, Robert B ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; EVALUATION; FEMALE; GENETICS; LABORATORY; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PREDICTION AND FORECASTING; PROTO ONCOGENE; REPRODUCIBILITY; STANDARD;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745986327     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.4744     Document Type: Article

References (37)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Sci-ence 235:177-182, 1987
2. Hayes DF, Thor AD: C-erbB-2 in breast can-cer: Development of a clinically useful marker. Se-min Oncol 29:231-245, 2002
3. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
4. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing met-astatic breast cancer. J Clin Oncol 20:719-726, 2002
5. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
6. Mass RD, Press M, Anderson S, et al: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6:240-246, 2005
7. Fornier M, Risio M, Van Poznak C, et al: HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Hunting) 16: 1340-1348, 2002
8. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11.647-663, 2000
9. Thor AD, Berry DA, Budman DR, et al: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
10. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000
11. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001
12. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
13. Bianco AR, DeLaurentis M, Carlomagno C, et al: 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between C-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 17:97a, 1998 (abstr 373)
14. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
15. Dybdal N, Leiberman G, Anderson B, et al: Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 93:3-11, 2005
16. Perez EA, Suman VJ, Davidson NE, et al: Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the NCCTG N9831 Intergroup adjuvant trial. J Clin Oncol 22:3700-3704, 2004
17. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
18. Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857, 2002
19. Cell Markers and Cytogenetics Committees College of Pathologists: Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 126:803-808, 2002
20. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154, 2002
21. Jenkins RB, Qian J, Lieber MM, et al: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531, 1997
22. Mascarello JT, Brothman AR, Davison K, et al: Cytogenetics Resource Committee of the College of American Pathologists and American College of Medical Genetics: Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probes. Arch Pathol Lab Med 126:1458-1462, 2002
23. Westgard JO, Barry PL, Hunt MR: A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem 27:493-501, 1981
24. Anderson S, Reddy J, Rai S, et al: Concordance between central and local laboratory IHC and FISH HER2 testing in a community-based trial of first-line trastuzumab plus a taxane in HER2-positive metastatic breast cancer. J Clin Oncol 23:851, 2004 (suppl; abstr 9580)
25. Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3-hour infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2-positive MBC and randomized for T in HER2-normal MBC. J Clin Oncol 23:14, 2004 (suppl; abstr 512)
26. Press MF, Slamon DJ, Flom KJ, et al: Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095-3105, 2002
27. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
28. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002
29. Hammond ME, Barker P, Taube S, et al: Standard reference material for HER 2 testing: Report of a National Institute of Standards and →Technology- sponsored consensus workshop. Appi lmmunohistochem Mol Morphol 11:103-106, 2003
30. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000
31. Press MF, Hung G, Godolphin VV, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
32. O'Leary TJ: Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol 9:3-8, 2001
33. Zarbo RJ, Hammond ME: Conference summary, Strategic Science symposium: HER-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 127:549-553, 2003
34. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clin-ical Oncology. J Clin Oncol 19:1865-1878, 2001
35. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology. Breast Cancer v 2, 2006. http://www.nccn.org/professionals/ physician_gls
36. Yaziji H, Gown AM: Accuracy and precision in HER2/neu testing in breast cancer: Are we there yet? Hum Pathol 35:143-146, 2004
37. Elkin EB, Weinstein MC, Winer EP, et al: HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 22:854-863, 2004